[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Piovanello P, Viola V, Costa G, Carletti M, Cecera A, Turchetta F, Iudicone R, Catalano G, Santucci A, Recchia F, Fiorillo L, Menichella MA, Baiano G: Locally advanced leiomyosarcoma of the spleen. A case report and review of the literature. World J Surg Oncol; 2007;5:135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced leiomyosarcoma of the spleen. A case report and review of the literature.
  • BACKGROUND: Leiomyosarcomas are rare tumours, predominantly localized in the stomach, small intestine and retroperitoneum.
  • Only one case of primary leiomyosarcoma of the spleen is described in human beings in literature.
  • CASE PRESENTATION: We report a case of locally advanced primary leiomyosarcoma of the spleen in a 54 year-old woman, diagnosed only after splenectomy, performed with the suspicion of splenic haematoma.
  • CONCLUSION: Due to the lack of cases, no specific chemotherapy regimen has been tested to provide a longer survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2001 Nov;130(5):893-4 [11685201.001]
  • [Cites] Acta Radiol. 1994 Sep;35(5):455-8 [8086253.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] J Am Vet Med Assoc. 1989 Sep 15;195(6):784-8 [2551865.001]
  • [Cites] J Am Vet Med Assoc. 1992 Oct 1;201(7):1077-9 [1429139.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • (PMID = 18045454.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2221972
  •  go-up   go-down


2. Matsutani T, Onda M, Miyashita M, Hao K, Yokoyama S, Matsuda T, Futami R, Takubo K, Sasajima K: Liver abscesses associated with stromal tumour of the stomach in a young woman. Eur J Gastroenterol Hepatol; 2001 Dec;13(12):1485-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver abscesses associated with stromal tumour of the stomach in a young woman.
  • She was found to have liver abscesses and a gastric submucosal mass by computed tomography and ultrasonography.
  • Gastroscopy and a barium swallow revealed a round submucosal mass with a giant ulceration in the body of the stomach.
  • Cultures of the fluid from a liver abscess and gastric juice yielded alpha-haemolytic streptococci.
  • The tumour was diagnosed as a stromal tumour of the stomach (leiomyosarcoma) in the final histological report.
  • The patient was discharged on postoperative day 17 without receiving adjuvant radio-chemotherapy.
  • This is a rare case of a liver abscess associated with a stromal tumour of the stomach in a young patient.
  • [MeSH-major] Leiomyosarcoma / complications. Liver Abscess / complications. Liver Abscess / microbiology. Stomach Neoplasms / complications
  • [MeSH-minor] Adult. Candida / isolation & purification. Disease-Free Survival. Female. Humans. Micrococcus / isolation & purification. Neisseria / isolation & purification. Streptococcus pyogenes / isolation & purification. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11742198.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Swann HM, Holt DE: Canine gastric adenocarcinoma and leiomyosarcoma: a retrospective study of 21 cases (1986-1999) and literature review. J Am Anim Hosp Assoc; 2002 Mar-Apr;38(2):157-64
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine gastric adenocarcinoma and leiomyosarcoma: a retrospective study of 21 cases (1986-1999) and literature review.
  • This retrospective study describes the clinical course, treatment, and outcome of 21 dogs with gastric adenocarcinomas (n=19) and leiomyosarcomas (n=2).
  • Medical records from 1986 to 1999 were reviewed for signalment, weight, diagnosis, tumor location, clinical signs, radiographic imaging procedures, surgical procedures, chemotherapy, duration of follow-up monitoring, outcome, cause of death, metastatic rate, metastatic sites, and method of detection of metastasis.
  • Fourteen of 19 (74%) dogs with gastric adenocarcinomas had metastasis.
  • Metastatic sites included gastric lymph nodes, omentum, liver, duodenum, pancreas, spleen, esophagus, adrenal glands, and lungs.
  • Both cases of a gastric leiomyosarcoma had metastatic disease involving the liver (n=2) and duodenum (n=1).
  • Surgery, consisting of either a Billroth I or a gastrojejunostomy, provided immediate relief of the gastric outflow obstruction and clinical improvement in the early postoperative period.
  • The beneficial effects of chemotherapy alone or adjuvant chemotherapy are still unknown.
  • The long-term prognosis for most cases of gastric adenocarcinomas and leiomyosarcomas is poor because of the presence of advanced disease.
  • Surgical resection, however, does alleviate gastric outflow obstruction in the immediate postoperative period.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / epidemiology. Leiomyosarcoma / veterinary. Stomach Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Dogs. Female. Male. Neoplasm Metastasis. Pennsylvania / epidemiology. Records as Topic / veterinary. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908834.001).
  • [ISSN] 0587-2871
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


Advertisement
4. Nakajima Y, Kakizaki S, Kanda D, Shimada Y, Sohara N, Sato K, Takagi H, Mori M, Watanabe H: Pancreatic and gastric metastases of leiomyosarcoma arising in the left leg. Int J Clin Oncol; 2005 Oct;10(5):342-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic and gastric metastases of leiomyosarcoma arising in the left leg.
  • Pancreatic or gastric metastases from other primary malignancies are rare, especially from leiomyosarcoma.
  • We report a case of leiomyosarcoma in the left lower leg with metastases to the pancreas and stomach.
  • Two years before presentation at our hospital, he had undergone surgical resection of leiomyosarcoma in the left lower leg and systemic chemotherapy for multiple metastatic tumors in the lung.
  • On admission, endoscopic examination and computed tomography were performed for a routine checkup to exclude esophageal varices and liver tumor.
  • Although the patient had no specific symptoms, multiple gastric and pancreatic metastases were identified by endoscopy and computed tomography, respectively.
  • In general, metastases to the pancreas and stomach are rare.
  • We discuss the clinical and diagnostic findings of pancreatic and gastric metastases by reviewing previously reported cases.
  • [MeSH-major] Leg. Leiomyosarcoma / secondary. Muscle Neoplasms / pathology. Pancreatic Neoplasms / secondary. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2004 Jun;444(6):527-35 [15057558.001]
  • [Cites] AJR Am J Roentgenol. 1993 Jan;160(1):49-52 [8416644.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1675-7 [14571814.001]
  • [Cites] Hepatogastroenterology. 2000 Mar-Apr;47(32):540-4 [10791233.001]
  • [Cites] Radiographics. 1998 Mar-Apr;18(2):369-78 [9536484.001]
  • [Cites] Acta Radiol. 1989 Nov-Dec;30(6):615-9 [2631949.001]
  • [Cites] J Comput Assist Tomogr. 1994 Nov-Dec;18(6):905-10 [7962797.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):675-9 [12167582.001]
  • [Cites] Radiology. 1986 Aug;160(2):399-402 [3523591.001]
  • [Cites] J Surg Oncol. 2003 Jul;83(3):161-6; discussion 166 [12827684.001]
  • [Cites] Pathol Int. 2001 Sep;51(9):686-90 [11696171.001]
  • [Cites] Eur Radiol. 1999;9(4):711-4 [10354890.001]
  • [Cites] Pathol Int. 2000 Feb;50(2):162-5 [10792777.001]
  • [Cites] J Orthop Sci. 2000;5(5):463-9 [11180903.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1324-30 [15446551.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • [Cites] Surg Gynecol Obstet. 1989 Apr;168(4):345-7 [2928909.001]
  • (PMID = 16247662.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Lam MM, Corless CL, Goldblum JR, Heinrich MC, Downs-Kelly E, Rubin BP: Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. Int J Gynecol Pathol; 2006 Jul;25(3):288-92
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most GISTs arise in the stomach and small bowel, whereas a small number occur elsewhere in the GI tract.
  • The original diagnoses were leiomyoma in one case and leiomyosarcoma in 2 cases.
  • Misdiagnosis may lead to inappropriate therapy because conventional chemotherapy and radiotherapy are not effective in the treatment of GISTs, whereas imatinib mesylate (Gleevec, Glivec) has a proven role in managing these tumors.
  • Thus, it is imperative to consider EGISTs in the differential diagnosis of mesenchymal neoplasms in the vulvovaginal/rectovaginal septum.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Rectal Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Benzamides. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Leiomyoma / chemistry. Leiomyoma / diagnosis. Leiomyoma / genetics. Leiomyoma / pathology. Leiomyosarcoma / chemistry. Leiomyosarcoma / diagnosis. Leiomyosarcoma / genetics. Leiomyosarcoma / pathology. Middle Aged. Mutation / genetics. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / analysis. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810068.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / DNA, Neoplasm; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


6. Melichar B, Voboril Z, Nozicka J, Cerman J Jr, Melicharová K, Mergancová J, Filip S, Krajina A, Voboril R, Jandík P: Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases. Tumori; 2005 Jan-Feb;91(1):19-23
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases.
  • The experience with liver-directed therapies, eg hepatic arterial infusion, in these patients is limited.
  • METHODS: Six patients with sarcoma metastatic to the liver (4 patients with gastrointestinal stromal tumors and 2 patients with leiomyosarcoma) were treated by hepatic arterial infusion in our center over a 12-year period.
  • RESULTS: None of the 5 assessable patients responded to the therapy, and liver metastases progressed in all patients.
  • CONCLUSIONS: Hepatic arterial infusion has little efficacy in the treatment of sarcoma metastatic to the liver.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hepatic Artery. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Sarcoma / drug therapy. Sarcoma / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Infusions, Intra-Arterial. Jejunal Neoplasms / pathology. Male. Middle Aged. Rectal Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850000.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kikuchi H, Konn H, Kamiya K, Baba M, Ohta M, Kondo K, Hiramatsu Y, Yamamoto M, Tanaka T, Sugimura H, Ohashi M, Kanda T, Nakamura S: [Two cases of postoperative recurrence of gastric GIST treated by imatinib]. Gan To Kagaku Ryoho; 2004 Oct;31(10):1569-73
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of postoperative recurrence of gastric GIST treated by imatinib].
  • Case 1: This 63-year-old Japanese man received a partial gastrectomy for leiomyosarcoma in 1993.
  • Though the response to treatment was SD-PR initially, a CT scan 15 months after initial treatment demonstrated the regrowth of the tumor in his liver.
  • The response to treatment was SD, and continued for 12 months.
  • IM is the treatment of choice for unresectable recurrence of GIST.
  • Both basic and clinical research is necessary to increase the therapeutic efficacy of IM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrectomy. Gastrointestinal Neoplasms / drug therapy. Leiomyosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Benzamides. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Imatinib Mesylate. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Protein-Tyrosine Kinases / antagonists & inhibitors. Thyroid Neoplasms / secondary

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15508453.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


8. Zhang H, Kong Y, Zhang H, He X, Zhang HY, Liu C, Xiao M, Xu X: Leiomyosarcoma of the inferior vena cava: case report and treatment of recurrence with repeat surgery. Ann Vasc Surg; 2010 Apr;24(3):417.e5-9
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the inferior vena cava: case report and treatment of recurrence with repeat surgery.
  • Leiomyosarcoma of the inferior vena cava (IVC) is an extremely rare malignancy with poor prognosis due to late diagnosis.
  • Surgical resection currently remains the best treatment; however, recurrence frequently occurs and the 5-year survival rate is only 31%.
  • The aim of this study is to report a case of IVC leiomyosarcoma and treatment of recurrence with repeat surgery.
  • A 36-year-old woman with a high-grade leiomyosarcoma originating from the infrahepatic IVC underwent an en bloc excision of the tumor.
  • Since the patient showed no response to adjuvant chemotherapy (i.e., a combination of 5-fluorouracil and gemcitabine), repeat operations were used as the main treatment modality for recurrence.
  • The median time to recurrence was 15 months (range 8-27).
  • The middle and upper IVC segments were involved in the local recurrence, and metastatic lesions occurred in multiple sites including the stomach, omentum, mesentery, left liver, and pelvic cavity.
  • Our results suggest that in the setting of chemotherapy-refractory IVC leiomyosarcoma repeat surgery may be an alternative treatment for recurrence and improve survival time.
  • [MeSH-major] Abdominal Neoplasms / surgery. Digestive System Surgical Procedures. Leiomyosarcoma / surgery. Neoplasm Recurrence, Local. Pelvic Neoplasms / surgery. Vascular Neoplasms / surgery. Vascular Surgical Procedures. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Drug Resistance, Neoplasm. Female. Humans. Reoperation. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20036495.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Des Guetz G, De Mestier P, Pierga JY: [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)]. J Chir (Paris); 2002 Oct;139(5):268-73
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
  • [Transliterated title] Enfin un traitement efficace dans les sarcomes digestifs indifférenciés (tumeurs stromales).
  • Gastrointestinal stromal tumors (GISTs) are non differentiated sarcoma of the gastrointestinal tract and have for a long time been confused with well differentiated tumors and classified as leiomyosarcoma.
  • Recent studies have found that an inhibitor of specific tyrosine kinase is effective in the treatment of GIST with an estimated response rate of more than 60%.
  • This new drug could significantly improve the prognosis of these aggressive chemoresistant tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Benzamides. Diagnosis, Differential. Drug Resistance, Neoplasm. Humans. Imatinib Mesylate. Immunohistochemistry. Leiomyosarcoma / diagnosis. Middle Aged. Mutation. Prognosis. Proto-Oncogene Proteins c-kit / genetics. Randomized Controlled Trials as Topic. Stomach / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Chir (Paris). 2002 Dec;139(6):368.
  • (PMID = 12410126.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


10. Rogiers X, Brunken C: Surgical management of hepatic metastatic disease. Saudi Med J; 2000 Jun;21(6):519-22
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radical surgical resection, if possible, is the treatment of choice.
  • Radical resection of metastases from wilms-tumor, carcinoids, carcinoma of the breast, hypernephroma, adrenal tumors, malignant melanoma, leiomyosarcoma and gastric cancer may improve long time survival, however knowledge is too small for giving general directions.
  • Local destructive therapies are only beneficial when a total necrosis of the tumor is reached.
  • Indications for this treatment are quite rare.
  • Both, systemic and local chemotherapy offers only palliation with little influence on long time survival.
  • Adjuvant and neo-adjuvant chemotherapy is applicated under study conditions with encouraging results.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colorectal Neoplasms / pathology. Europe / epidemiology. Humans. Patient Selection. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11508246.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 17
  •  go-up   go-down


11. Steinert DM, Blakely LJ, Patel SR, Burgess MA, Chen LL, Trent JC, Raymond AK, Benjamin RS: Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):9047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy.
  • In the era of kit immunohistochemistry and imatinib mesylate therapy the outcome of IASs is unknown.
  • METHODS: We analyzed 268 consecutive patients who were referred to our institution for evaluation of the diagnosis of GIST from 12/15/00 to 9/1/01.
  • Patients diagnosed with GIST were treated with imatinib mesylate, and patients diagnosed with other IAS were treated with standard sarcoma chemotherapy.
  • Another 46 patients were excluded because no data were available at the time of this abstract.
  • Of the remaining 218 patients, 159 (72.9%) were GIST and 59 (27.1%) were IAS specifically: 31 leiomyosarcoma, 10 spindle cell tumors, 4 unclassified sarcomas, and 14 other types of sarcoma.
  • The most common primary tumor sites for patients with GIST were stomach (37.1%), small bowel (34%), and colon (6.3%); whereas, patients with other intra-abdominal sarcomas occurred in the retroperitoneum (25.4%), abdominal viscera (18.6%), and pelvis (11.9%).
  • While median survival from the time of diagnosis has not been reached in patients with GIST, in other IAS median survival is 63.8 months.
  • Time to progression in patients with GIST was 16.4 months after imatinib and 5.1 months in patients with IAS treated with standard sarcoma chemotherapy.
  • CONCLUSIONS: Survival and time to progression are worse for IAS compared to GISTs.
  • New therapies for these tumors are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Maksimovic S: Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience. Med Arh; 2010;64(2):116-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience.
  • PURPOSE: Gastric cancer (GC) remains one of the most frequent cancers worldwide.
  • The double tract (DT) method is the optimal reconstruction procedure aftertotal gastrectomy for patients with gastric cancer.
  • Tumor diffused in the sections of stomach in 37 cases: cardia and body in 14 cases, body and antrum in 16 cases, and in only body of stomach in 7 cases.
  • In the pathological examination, the tumors of 34 patients were diagnosed as adenocarcinoma, 2 as malignant lymphoma, and i as leiomyosarcoma.
  • CONCLUSIONS: The benefits of this method are (1) a simple procedure;.
  • [MeSH-major] Digestive System Surgical Procedures. Gastrectomy / rehabilitation. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514781.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


13. Li J, Liu P, Wang H, Yu J, Xie P, Liu X: [Clinical analysis of 31 patients with gastric stromal tumors]. Zhonghua Nei Ke Za Zhi; 2002 Nov;41(11):742-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 31 patients with gastric stromal tumors].
  • OBJECTIVE: To investigate the clinical manifestations, diagnosis and treatment of gastric stromal tumors.
  • METHODS: 31 patients with gastric stromal tumors treated from 1993, 1 - 2001, 9 were analyzed retrospectively.
  • The distribution of gastric tromal tumors is fundus > body > antrum.
  • Diagnosis of this condition is sometimes difficult and treatment is often delayed because patients usually present with nonspecific abdominal symptoms.
  • The main manifestations of gastric stromal tumors are upper gastrointestinal hemorrhage 61.3% (19/31), 7 patients with acute hemorrhage and 12 with chronic hemorrhage.
  • Gastroscopy, ultrasound gastroscopy, computed tomography, B type ultrasound and upper gastrointestinal X-ray series are helpful to diagnosis.
  • But the final diagnosis is decided by pathological and immunohistochemistry examinations.
  • Gastric stromal tumors exhibit consistent immunohistochemical expressions of CD(117) and/or CD(34).
  • The operative treatment is thought of the first choice.
  • Effect of the chemotherapy isn't satisfied.
  • There is no standard chemotherapy for gastric stromal tumors.
  • CONCLUSIONS: Gastric stromal tumor is a kind of separated submucosal tumor which is different from leiomyoma, leiomyosarcoma and neurogenic tumors.
  • Pathological and immunohistochemistry inspectations are very important to make clear diagnosis.
  • Early diagnosis and rational treatment are the keys to improve the prognosis.
  • [MeSH-major] Stomach Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485519.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Thong-Ngam D, Tangkijvanich P, Mahachai V, Kullavanijaya P: Current status of gastric cancer in Thai patients. J Med Assoc Thai; 2001 Apr;84(4):475-82
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of gastric cancer in Thai patients.
  • To determine the current status in various aspects of gastric cancer in Thai patients, we retrospectively reviewed the records of 119 patients with histologically proven gastric cancer in King Chulalongkorn Memorial Hospital during the five-year period from 1994 to 1998.
  • Lesion location was lower third in 40.3 per cent, middle third in 31.9 per cent, upper third in 15.1 per cent and entire stomach in 3.4 per cent of patients.
  • Adenocarcinoma was the most common histological finding (91.6%), followed by lymphoma and leiomyosarcoma (3.4% each).
  • Management was surgical treatment in 58.9 per cent (total gastrectomy 14.5%, subtotal gastrectomy 33.3% and palliative bypass surgery in 11.1%).
  • Systemic chemotherapy was the primary modality of therapy in 16.8 per cent and was adjuvant therapy in 18.5 per cent.
  • The median survival time of resectable cases was 1.00+/-0.53 years, significantly longer than that of unresectable cases (0.11+/-0.03 years) (p=0.0025).
  • However, the administration of chemotherapy did not improve the survival rate.
  • It is concluded that, in Thailand, gastric cancer continues to be an important health problem and is generally associated with a poor prognosis.
  • [MeSH-major] Stomach Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11460956.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


15. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM: Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol; 2007 Sep;5(8):355-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gastroparesis: pathogenesis and management of an underrecognized disorder.
  • Gastroparesis is a disorder of the stomach caused by delayed gastric emptying in the absence of mechanical obstruction.
  • Gastroparesis has been described as a complication of several malignancies, including gastric, pancreatic, gallbladder, esophageal, and lung cancers, as well as leiomyosarcoma.
  • In the setting of malignancy, gastroparesis may result from the cancer itself or may be a complication of its treatment with such modalities as surgery, radiation therapy, or chemotherapy.
  • Appropriate treatment of MG may help to avoid serious consequences, such as cancer cachexia, intolerance of oral anticancer agents, dehydration, and hospitalization.
  • [MeSH-major] Gastric Emptying. Gastrointestinal Agents / therapeutic use. Gastrointestinal Motility / drug effects. Gastroparesis / etiology. Neoplasms / complications
  • [MeSH-minor] Cathartics / therapeutic use. Humans. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Gastroparesis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Support Oncol. 2007 Sep;5(8):368-70 [17944145.001]
  • [CommentIn] J Support Oncol. 2007 Sep;5(8):366-7 [17944144.001]
  • (PMID = 17944143.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cathartics; 0 / Gastrointestinal Agents
  • [Number-of-references] 52
  •  go-up   go-down


16. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA: Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg; 2006 Jun;141(6):537-43; discussion 543-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The primary sarcoma site was the abdomen or retroperitoneum (n = 22), stomach (n = 18), small or large bowel (n = 17), pelvis (n = 4), uterus (n = 3), or other (n = 2).
  • Tumor pathologic types included gastrointestinal stromal tumor (n = 36), leiomyosarcoma (n = 18), and sarcoma not otherwise classified (n = 12).
  • Treatment with radiofrequency ablation (either alone or combined with resection) (P = .002) and lack of adjuvant chemotherapy (P = .01) predicted shorter disease-free survival.
  • CONCLUSIONS: Long-term survival can be achieved following surgical treatment of sarcoma liver metastasis, especially in patients with gastrointestinal stromal tumor.
  • Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Neoplasms / pathology. Disease-Free Survival. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Raffensperger J, Krueger R: Carney's triad: a 16-year follow-up. J Pediatr Surg; 2007 Aug;42(8):1452-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a female teenager who presented with a gastrointestinal stromal tumor of the stomach and a paraganglioneuroma.
  • She later developed a pulmonary chondroma, fulfilling the requirements of Carney's triad.
  • [MeSH-major] Chondroma / pathology. Ganglioneuroma / pathology. Leiomyosarcoma / pathology. Lung Neoplasms / pathology. Mediastinal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antidepressive Agents / therapeutic use. Combined Modality Therapy. Depressive Disorder / complications. Depressive Disorder / drug therapy. Fatal Outcome. Female. Follow-Up Studies. Gastrointestinal Stromal Tumors / complications. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Syndrome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706515.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents
  •  go-up   go-down


18. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF: Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol; 2000 Oct;7(9):705-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.
  • GISTs occur throughout the GI tract but are usually located in the stomach and small intestine.
  • Surgical resection remains the mainstay of treatment, as chemotherapy and radiation are ineffective.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Leiomyoma / pathology. Leiomyosarcoma / pathology. Neoplasms, Nerve Tissue / pathology
  • [MeSH-minor] Decision Trees. Humans. Prognosis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11034250.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 52
  •  go-up   go-down


19. Neagu S, Zărnescu NO, Costea R, Stamatoiu A, Badea V, Dumitrescu C, Grădinaru S, Sajin M, Ardeleanu C, Pelmuş M: [Gastric stromal tumors--Clinical and histopathological analysis of four cases]. Chirurgia (Bucur); 2003 Sep-Oct;98(5):443-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric stromal tumors--Clinical and histopathological analysis of four cases].
  • BACKGROUND: The aim of this study is to present our experience concerning a rare form of gastric tumor--gastrointestinal stromal tumor (GIST).
  • METHODOLOGY: We reviewed data of four patients with gastric stromal tumors, which have been admitted in our department from 1998-2002.
  • During surgery we discovered proximal gastric tumors with 4, 5, 10 and 20 cm in largest diameter.
  • We performed excision of the whole tumor with a security limit of 2 cm or gastric resection (one case), without limphadenectomy.
  • One patient developed an anastomotic fistula with a good evolution under conservative treatment.
  • Histopathological and immunohistochemical study diagnosed gastric stromal tumors by identifying the CD 117 maker.
  • Postoperatively neither one of our patients received chemotherapy or radiotherapy.
  • The other two patients are in a good condition up to date, without metastasis, one and respectively three years after surgical treatment.
  • CONCLUSIOUS: Correct diagnosis, complete tumor resection and surveillance are essential steps in management of gastric stromal tumors.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Male. Middle Aged. Proto-Oncogene Proteins c-kit / analysis. Retrospective Studies. Stromal Cells / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14999973.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


20. Jadvar H, Tatlidil R, Garcia AA, Conti PS: Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol; 2003 Mar;58(3):215-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography.
  • AIM: We retrospectively assessed the use of [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) in the evaluation of recurrent disease in patients with history of gastric malignancy.
  • MATERIALS AND METHODS: Eighteen patients were referred for FDG PET for evaluation of recurrent gastric cancer.
  • Prior treatments included total (n = 4) or partial gastrectomy (n = 14) followed by chemotherapy alone (n = 7) or combined chemoradiation therapy (n = 2).
  • The interval between the most recent treatment and PET ranged from 3 months to 2 years.
  • RESULTS: PET was concordant with computed tomography (CT) in 12 patients (5 TP, 6 TN, 1 FN).
  • Additional chemotherapy was initiated in these three patients (17% of total) based on PET localization of disease.
  • PET and a gastric anastomosis biopsy were negative in another patient with positive CT.
  • CONCLUSION: FDG PET may be useful in the evaluation of recurrent gastric cancer, and can localize the disease when CT is non-diagnostic.
  • Imaging evaluation with PET may also impact on the clinical management of patients with recurrent gastric cancer.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Leiomyosarcoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 The Royal College of Radiologists
  • [ErratumIn] Clin Radiol. 2003 Jul;58(7):570
  • (PMID = 12639527.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Artigau Nieto E, Luna Aufroy A, Dalmau Pórtulas E, Rebasa Cladera P, Orellana Fernández R, Darnell Martín A, Navarro Soto S, Pericay Pijaume C: Gastrointestinal stromal tumors: experience in 49 patients. Clin Transl Oncol; 2006 Aug;8(8):594-8
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Curative treatment continues to be radical resection of the tumour and is resistant to commonly employed chemotherapy regimens.
  • Imatinib mesilate is a drug that inhibits c-kit activity expressed by GIST and its activity in these tumours has been demonstrated.
  • MATERIAL AND METHODS: Retrospective study of all cases of leiomyoma, leiomyosarcoma, schwannoma, and stromal or mesenchymal tumors from 1989 to July 2004.
  • The lesion was located in small bowel (n = 22), stomach (n = 19), rectum (n = 3), peritoneum (n = 2), esophagus (n = 1), omentum (n = 1), and retroperitoneum (n = 1).
  • Two of the patients that did not undergo surgery received chemotherapy.
  • At the time of study, 28 (57.14%) patients remained alive, 23 (46.9%) of whom were disease- free and five (10.2%) were not.
  • Surgical resection continues being the best treatment to definitively cure this disease.
  • On the other hand, Imatinib is used in the treatment of the metastatic disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):669-76 [12152168.001]
  • [Cites] Surgery. 2003 Oct;134(4):656-65; discussion 665-6 [14605627.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):485-91 [12057094.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S37-8 [12528771.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Hum Pathol. 2002 May;33(5):466-77 [12094371.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Surg Oncol. 2000 Aug;9(2):67-70 [11094325.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3899-903 [10919666.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):244-51 [7531105.001]
  • [Cites] Cancer Invest. 2002;20(5-6):605-12 [12197215.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):41-7 [7817943.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Curr Treat Options Oncol. 2000 Aug;1(3):267-73 [12057170.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26 [11740803.001]
  • (PMID = 16952848.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement